Home >

Editorial Board

Editor in Chief

Jonathan S. Berek, MD, MMS, FASCO, is the Laurie Kraus Lacob Professor and Director of the Stanford Women’s Cancer Center at the Stanford Cancer Institute, where he specializes in gynecologic oncology. He is also Chair of the Department of Obstetrics and Gynecology at Stanford. An ASCO member since 1983, he is the Co-Chair of the Management of Cervical Cancer Guideline Expert Panel. He has also served on numerous other ASCO committees, including the Scientific Program Committee and the Cancer Education Committee.

Al B. Benson III, MD, FASCO, is a Professor of Medicine in the Division of Hematology/Oncology at Northwestern University's Feinberg School of Medicine, Associate Director for Clinical Investigations and Chair of the Clinical Protocol Scientific Review and Monitoring System for the Robert H. Lurie Comprehensive Cancer Center, and an Attending Physician at Northwestern Memorial Hospital. He specializes in gastrointestinal malignancies, including colorectal cancer. An ASCO member since 1985, he currently serves on the Gastrointestinal Guideline Advisory Group.
Susan Lerner Cohn, MD, is Director of Clinical Sciences, Section of Pediatric Oncology/Hematology, at Comer Children's Hospital at the University of Chicago. She is the Dean for Clinical Research for the Biological Sciences Division and a Professor of Pediatrics at the University of Chicago. She is one of a few pediatric oncologists conducting phase I clinical trials of treatments for neuroblastoma. An ASCO member since 1988, Dr. Cohn serves as Chair of the Bylaws Committee and as a Specialty Editor on the Cancer.Net Editorial Board.
Steven E. Finkelstein, MD, is a radiation oncologist and the Chief Science Officer and National Director of the Translational Research Consortium (TRC) at 21st Century Oncology in Arizona. He also serves as an Adjunct Associate Professor at Translational Genomic Research Institute (TGEN) and Editor in Chief of the journal Contemporary Radiation Oncology. He has been an ASCO member since 2003.
Sabha Ganai, MD, PhD, is a surgical oncologist and Director of Gastrointestinal Oncology at the Simmons Cancer Institute at Southern Illinois University.  Her professional interests include rural health geographics, translational research related to the mechanisms of metastasis, and ethics education. An ASCO member since 2011, she served on the ASCO University Fellows Council, and currently serves on the Ethics and Integrated Media and Technology Committees. Follow Dr. Ganai on Twitter @DrSabha.
Stuart A. (Skip) Grossman, MD, is a Professor of Oncology, Medicine, and Neurosurgery at the Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center. His clinical interests include developing novel therapeutic strategies for patients with primary and metastatic brain tumors, leptomeningeal metastases, and cancer pain. He joined ASCO in 1982.
Stephen Leong, MD, is an Associate Professor in the Division of Medical Oncology at the University of Colorado School of Medicine. His areas of interest are gastrointestinal malignancies and developmental therapeutics, where he focuses on investigating novel agents in colorectal cancers. He has been an ASCO member since 2005.
Robert G. Mennel, MD, FASCO, specializes in medical oncology and hematology at Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas, Texas. Dr. Mennel is board certified in both internal medicine and medical oncology; his primary research interest is head and neck cancers. An ASCO member since 1980, he has served on the Breast Cancer Tumor Markers, Gastrointestinal Tumor Markers, Cancer Education, and Oncology Training Programs Committees.
Hope S. Rugo, MD, is a medical oncologist specializing in breast cancer research and treatment at the University of California, San Francisco. She is a Professor of Medicine, Director of the Breast Oncology and Clinical Trials Education, and the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer. Dr. Rugo has been a member of ASCO since 1994, serving on the Scientific Program, Cancer Education, and Membership Committees. Currently, she serves on the Breast Cancer Consensus Panel and the Breast Cancer Symposium Program Committee.
Alan Sandler, MD, is Principal Medical Director for Genentech. He is the author or co-author of more than 200 published articles, book chapters, reviews, and abstracts involving the clinical activity of chemotherapy and novel targeted agents, with a particular emphasis on lung cancer. An ASCO member since 1993, he has served on the Cancer Education and Scientific Program Committees.
Jennifer S. Temel, MD, is the Clinical Director of Thoracic Oncology and Director of Cancer Outcomes Research at the Massachusetts General Hospital (MGH) Cancer Center. Her area of research interest is palliative and end-of-life care in patients with advanced cancer. An ASCO member since 2002, Dr. Temel currently sits on the Palliative Care in Oncology Symposium Planning Committee and the Journal of Clinical Oncology Editorial Board.